An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of S-033188 after Administration of a Single Dose to Otherwise Healthy Pediatric Patients Aged 6 Months to < 12 Years with Influenza
Phase 3
- Conditions
- Influenza A and/or B virus infection
- Registration Number
- JPRN-jRCT2080223362
- Lead Sponsor
- Shionogi & Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients confirmed with influenza virus infection and within 48 hours from onset.
Age: 6 months old or more 11years old or less
Exclusion Criteria
- Patients with severe symptoms of influenza virus infection requiring inpatient treatment.
- Patients with high risk factors.
- Patients with concurrent infections requiring antimicrobial therapy.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, efficacy, pharmacokinetics
- Secondary Outcome Measures
Name Time Method